Articles from Mevion Medical Systems

Mevion Medical Systems today announced that Huntsman Cancer Institute at the University of Utah has signed a contract for a second MEVION S250i Proton Therapy System.

Mevion Medical Systems, the leader in compact proton therapy solutions, proudly announces the delivery of its first MEVION S250-FIT Proton Therapy System™* to Stanford Health Care. This marks a significant milestone in the development of proton therapy, as it is the first time a full proton therapy system is to be installed in a room like a conventional linear accelerator (LINAC) vault. The new system represents a new frontier in proton therapy, integrating cutting-edge technology to enhance patient outcomes.

Mevion Medical Systems, a leading provider of compact proton therapy solutions, today announced that it has received approval from the National Medical Products Administration (NMPA) of China for its MEVION S250i Proton Therapy System. This marks the first time this advanced technology has been approved in China, making Mevion the first company to offer a compact, integrated proton solution to Chinese cancer patients.

Please replace the release with the following corrected version due to multiple revisions.

Mevion Medical Systems, the leading provider of compact proton therapy systems, today announced a partnership with Nebraska Medicine to integrate the MEVION S250-FIT Proton Therapy System™* into the Fred & Pamela Buffett Cancer Center in Omaha, Nebraska. This marks the second National Cancer Institute (NCI)-designated cancer center to consider Mevion’s FIT™ proton therapy solution, and could be one of the first S250-FIT™ installations along with Stanford Health Care, BayCare, and Atlantic Health highlighting the growing adoption of the benefits of this innovative technology.

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is redefining access to this advanced treatment, empowering healthcare systems to Re-Imagine cancer care. At the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), Mevion will highlight its latest advancements, including the transformative MEVION S250-FIT Proton Therapy System™*, designed to be installed in existing LINAC vaults, and the MEVION S250i Proton Therapy System®, the most compact proven gantry-based solution.

BayCare, a leading not-for-profit health care system, announces the groundbreaking of a $33 million expansion to the BayCare Cancer Institute at St. Joseph's Hospital that will house the revolutionary MEVION S250-FIT Proton Therapy System*. BayCare will be the first to offer this advanced therapy in Tampa, Florida, with the facility expected to be operational by the end of 2025.

Atlantic Health System, an integrated health care system setting standards for quality health care in New Jersey, Pennsylvania and the New York metropolitan area, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System™* at the Carol G. Simon Cancer Center, located at Morristown Medical Center in New Jersey. The proton system is scheduled to be installed in 2025, and once in use will usher in a new era of cutting-edge radiation oncology services.

Kansas City Proton Institute (KCPI), the first physician-led proton therapy center in the Midwest, and Mevion Medical Systems announced today that the first four patients were treated at Kansas City Proton Institute on Dec. 19, with the MEVION S250i Proton Therapy System®.

Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.

Mevion Medical Systems, the leading global provider of compact proton therapy systems for use in radiation treatment for cancer patients, announces the launch of 'Mevion Capital' in the US and Canada. This initiative offers customized proton therapy finance solutions to healthcare communities including health systems, hospitals, physician groups, and cancer centers, addressing a critical need in the industry for accessible capital and industry-relevant financial structures.

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting (ASTRO 2023).

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the 15-ton compact accelerator for the MEVION S250i Proton Therapy System® was delivered on January 20, to Kansas City Proton Institute (KCPI). This milestone marks the beginning of the first true compact proton therapy system installation in Kansas City, and the fourth in the region.

Mevion Medical Systems is pleased to announce it has entered into a contract with the Froedtert & the Medical College of Wisconsin health network to bring the MEVION S250i Proton Therapy System® to Wisconsin.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System™ with HYPERSCAN® Pencil Beam Scanning (PBS). Stanford Health Care has been selected as the first site where the system will be developed and installed.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System™.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System® was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China. This milestone commences the system installation at Tongji Hospital’s proton therapy center, the first of its kind in Central China.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the first patient was treated at the David C. Pratt Cancer Center at Mercy Hospital St. Louis on July 5th with the MEVION S250i Proton Therapy System®.

Mevion Medical Systems announced today that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS) in a comprehensive hospital in Southern China.

Ackerman Cancer Center (ACC), the world’s first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient. The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018.

Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System® in Wuhan, China.

Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center. It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer.

Mevion Medical Systems is pleased to announce it has signed a contract with Kansas City Urology Care (KCUC) for the purchase of a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning technology.

RaySearch Laboratories AB (publ) and Mevion Medical Systems, two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH delivery with the MEVION S250i Proton Therapy System.

DYN’R Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, are delighted to announce the launch of a new gating option for their joint customers.

Mevion Medical Systems announced today that it has delivered the 15-ton compact accelerator to Mercy Hospital St. Louis in Missouri. The accelerator, the world’s smallest, is the core of the MEVION S250i Proton Therapy System® which precisely delivers therapeutic doses of radiation to tumors while preserving healthy tissue and critical organs.

Mevion Medical Systems today announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11th with the MEVION S250i Proton Therapy System®. Despite the challenges of the COVID-19 pandemic, the Mevion team successfully installed the MEVION S250i in 7 months from the delivery of the accelerator.

Mevion Medical Systems today announced the upgrade of the MEVION S250 Proton Therapy System at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, to a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning and FLASH capabilities. Originally installed and treating patients since 2013, the MEVION S250 was the first compact proton therapy system in the world.

Mevion Medical Systems today announced that Jay S. Loeffler, MD, has been appointed Co-Chair of Mevion Medical Systems Medical/Technical Advisory Board. Dr. Loeffler, a leading expert in the treatment and management of brain tumors with proton therapy, has been the Chief of the Department of Radiation Oncology at Massachusetts General Hospital (MGH) and Professor of Radiation Oncology and Neurosurgery at Harvard Medical School for over twenty years.